Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb;69(2):143-148.
doi: 10.1007/s00105-017-4062-9.

[Profile of Kaposi sarcoma patients in the competence network HIV/AIDS]

[Article in German]
R-E Klingenberg  1 , S Esser  2 , N H Brockmeyer  1   3 , C Michalik  3   4 , A Skaletz-Rorowski  1   3 , A Potthoff  5 ; Kompetenznetz HIV/AIDS
Affiliations

[Profile of Kaposi sarcoma patients in the competence network HIV/AIDS]

[Article in German]
R-E Klingenberg et al. Hautarzt. 2018 Feb.

Abstract

Background: Kaposi's sarcoma (KS) represents the most common AIDS-defining neoplasm. Only very few studies regarding the course and treatment of human immunodeficiency virus (HIV)-associated KS have been carried out in Germany.

Objective: In this study the course of HIV-associated KS was observed in patients from the cohort database of the competence network for HIV/AIDS.

Material and methods: Data from HIV-associated KS patients from 9 German core centers from 1987 to 2011 were retrospectively collected. Kaplan-Meier curves for the recurrence and survival probability were calculated.

Results: In 222 patients KS was diagnosed at a median age of 38.5 ± 10.1 years. Men were almost exclusively affected (97.7%). The HIV viral load at the time of diagnosis was in 7.4% <50 copies/ml. Of the patients 55.5% developed KS with a CD4 cell count of <200 cells/μl and 9.5% with >500 cells/μl. In 68 patients KS therapy consisted exclusively of the optimization or initiation of antiretroviral therapy (ART). In addition, 71 patients were treated with pegylated liposomal doxorubicin. During the median follow-up period of 8.9 ± 4.9 years, 80.2% of the patients were free of KS recurrence. Survival rates after 5 and 10 years were 96.8% and 91.3%, respectively.

Conclusion: Even with a good immune status HIV-associated KS occurred. An effective ART was the most important mainstay of therapy. With appropriate therapy, HIV-positive patients with KS showed a good survival rate.

Keywords: Antiretroviral therapy; CD4+ cell counts; HIV infections; Recurrence; Survival.

PubMed Disclaimer

References

    1. J Clin Oncol. 2014 Feb 10;32(5):409-14 - PubMed
    1. N Engl J Med. 2015 Aug 27;373(9):795-807 - PubMed
    1. Eur J Cancer. 2001 May;37(7):878-83 - PubMed
    1. N Engl J Med. 2007 Sep 27;357(13):1352-3 - PubMed
    1. Eur J Med Res. 2009 Aug 12;14(8):323-31 - PubMed

MeSH terms